Glaxo receives FDA 'complete response' for cervical cancer vaccine

Armen Hareyan's picture
Advertisement

GlaxoSmithKline (NYSE: GSK) announced today that it has received a complete response letter from the U.S. Food and Drug Administration related to its application for the cervical cancer vaccine, CERVARIX

Advertisement